NCT07268196

Brief Summary

Liver Transplantation (LT) is a lifesaving intervention with around 90% of recipients currently surviving the first postoperative year and subsequent life expectancy now exceeding 20 years. After the post-operative recovery period, however, LT recipients become more and more confronted with the challenges of re-engagement with life after transplantation, a need to reach a new stability, reestablish function in everyday life, reconnect with valued roles, regain independence, and resume work Sexual function is a very important parameter in the evaluation of Quality of Life (QoL), as it has been shown that sexual dysfunction in transplant patients is associated with increased depression and decreased QoL. There are several studies in the relevant literature supporting the recovery of sexual function in patients after liver transplantation. It has been found that recovery was observed in erectile dysfunction in male patients 6 months after liver transplantation.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
6mo left

Started Dec 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress48%
Dec 2025Oct 2026

First Submitted

Initial submission to the registry

November 22, 2025

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 5, 2025

Completed
2 days until next milestone

Study Start

First participant enrolled

December 7, 2025

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 23, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 23, 2026

Last Updated

December 31, 2025

Status Verified

December 1, 2025

Enrollment Period

11 months

First QC Date

November 22, 2025

Last Update Submit

December 24, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Evaluation of sexual function by questionnaire method

    Arizona Sexual Experience Scale (ASEX) scores for sexual dysfunction, ASEX scores are 5 point questionnaire with scores given for each question from 1-6. Total scores More than or equal to 19 indicate sexual dysfunction (higher the scores greater the sexual dysfunction).

    pre transplant, 3,6,12 months

  • Evaluation of erectile dysfunction using questionnaire method

    International Index for Erectile Function - 5 (IIEF-5) scores for erectile dysfunction IIEF 5 scores are also a 5 point questionnaire with score ranging 0-6 for each question. Total scores less than 15 indicate mild to moderate erectile dusfunction and scores less than 11 indicate moderate erectile dysfunction (lower the scores higher the erectile dysfunction)

    pre transplant, 3,6,12 months

Secondary Outcomes (2)

  • Correlation between testosterone and Meld Na scores

    pre transplant, 3,6,12 months

  • Sarcopenia implication in recovery of sexual function.

    pre transplant, 3,6,12 months

Study Arms (1)

Chronic liver Disease

Chronic Liver disease patients undergoing elective liver transplantation

Other: No Treatment

Interventions

This is an Observational Study

Chronic liver Disease

Eligibility Criteria

Age18 Years - 60 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Chronic Liver Disease patients awaiting elective transplantation and post liver transplant patients.

You may qualify if:

  • Married male Patients.
  • Decompensated Chronic Liver Disease awaiting elective liver transplantation.
  • Post Liver Transplant patients with stable graft function.

You may not qualify if:

  • Negative consent.
  • Patients with ongoing medical and surgical issues (biliary complications, graft complication etc.).
  • Acute on Chronic Liver Failure and Acute Liver Failure patients.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

ILBS

New Delhi, National Capital Territory of Delhi, 110070, India

RECRUITING

MeSH Terms

Conditions

Fibrosis

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Prof. Dr. Viniyendra Pamecha, MS FEBS

    ILBS

    STUDY DIRECTOR

Central Study Contacts

Dr. Rajagopalan G, DNB

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 22, 2025

First Posted

December 5, 2025

Study Start

December 7, 2025

Primary Completion (Estimated)

October 23, 2026

Study Completion (Estimated)

October 23, 2026

Last Updated

December 31, 2025

Record last verified: 2025-12

Locations